Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ORMP |
---|---|---|
09:32 ET | 12423 | 2.3 |
09:35 ET | 6087 | 2.3 |
09:37 ET | 15029 | 2.3 |
09:39 ET | 18558 | 2.31 |
09:42 ET | 7066 | 2.2963 |
09:44 ET | 2445 | 2.2952 |
09:46 ET | 560 | 2.31 |
09:51 ET | 3100 | 2.2997 |
09:53 ET | 6866 | 2.29 |
09:57 ET | 500 | 2.2998 |
10:02 ET | 1500 | 2.295 |
10:04 ET | 1150 | 2.295 |
10:06 ET | 3000 | 2.2902 |
10:08 ET | 200 | 2.29 |
10:09 ET | 3000 | 2.2996 |
10:11 ET | 1000 | 2.2907 |
10:13 ET | 6000 | 2.295 |
10:15 ET | 5972 | 2.31 |
10:26 ET | 749 | 2.31 |
10:36 ET | 4140 | 2.33 |
10:38 ET | 350 | 2.34 |
10:42 ET | 800 | 2.3316 |
10:56 ET | 500 | 2.331 |
10:58 ET | 200 | 2.34 |
11:05 ET | 500 | 2.345 |
11:07 ET | 100 | 2.345 |
11:09 ET | 500 | 2.345 |
11:12 ET | 600 | 2.34 |
11:14 ET | 733 | 2.34 |
11:23 ET | 3000 | 2.3402 |
11:25 ET | 2259 | 2.34 |
11:50 ET | 100 | 2.34 |
12:10 ET | 100 | 2.33 |
12:28 ET | 2834 | 2.3358 |
12:51 ET | 100 | 2.335 |
01:11 ET | 1000 | 2.335 |
01:15 ET | 100 | 2.33 |
01:31 ET | 900 | 2.33 |
01:38 ET | 200 | 2.335 |
01:42 ET | 5100 | 2.335 |
02:00 ET | 100 | 2.33 |
02:45 ET | 1400 | 2.35 |
02:52 ET | 253 | 2.3463 |
03:15 ET | 986 | 2.35 |
03:17 ET | 100 | 2.345 |
03:21 ET | 595 | 2.345 |
03:32 ET | 100 | 2.345 |
03:35 ET | 200 | 2.345 |
03:37 ET | 210 | 2.342 |
03:51 ET | 300 | 2.35 |
03:55 ET | 1100 | 2.3401 |
03:57 ET | 100 | 2.34 |
04:00 ET | 2204 | 2.34 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Oramed Pharmaceuticals Inc | 93.5M | 4.7x | --- |
Chimerix Inc | 93.5M | -1.1x | --- |
Ovid Therapeutics Inc | 96.5M | -2.9x | --- |
Regulus Therapeutics Inc | 92.4M | -1.4x | --- |
Genenta Science SPA | 88.8M | -9.2x | --- |
InflaRx NV | 90.1M | -1.5x | --- |
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $93.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 40.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.69 |
EPS | $0.50 |
Book Value | $4.06 |
P/E Ratio | 4.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | 4.5x |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.